...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric Reports >Effectiveness and safety of flexible therapeutic schemes including first- and secondgeneration basal insulins during a pediatric summer diabetes camp
【24h】

Effectiveness and safety of flexible therapeutic schemes including first- and secondgeneration basal insulins during a pediatric summer diabetes camp

机译：柔性治疗方案的有效性和安全性，包括在儿科夏季糖尿病营地期间的第一代和第二代基底胰岛素

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Outcomes of insulin analogues in pediatric diabetes camps are poorly investigated; no data is available about insulin degludec (IDeg)Our aim was to assess impact of insulin therapy adopted by the participants to a 4day diabetes camp held in 2017, hypothesizing a possible excess risk of hypoglycemia in patients treated with IDeg Overall, 40 children with type 1 diabetes (mean age 134±30 years; 625% males) attended the camp (200% on continuous subcutaneous insulin infusion and 800% on multiple daily injections MDI) Among children in MDI regimen, 719% were treated with IDeg as basal insulin and 281% with glargine U100 (IGlar) All patients used Lispro or Aspart as shortacting insulin Daily plan of the camp included educational sessions, physical exercise, 3 main meals and 2 snacks At the arrival, IGlar and shortacting insulin doses were revised according to existing guidelines, while IDeg dose was revised based on an empirical individualized approach At the arrival, insulin doses were reduced in 22 participants (194±105%), while doses were increased in 17 children (+178±127%), based on individual needs No statistically significant betweengroup difference emerged in mean blood glucose and glucose variability No excess risk of hypoglycemia was found in the IDeg group The study suggests similar effectiveness and safety of different insulin schemes when associated with appropriate diabetes education and management, and flexible dose adjustments Despite its longer halflife and the lack of a validated algorithm, IDeg was not associated with an excess risk of hypoglycemia.
机译：小儿糖尿病阵营中胰岛素类似物的结果较差;关于胰岛素Degludec（IDEG）没有数据我们的目的是评估参与者通过2017年举行的第4天糖尿病阵营的胰岛素治疗的影响，假设IDEG治疗的患者的低血糖可能过度风险，40名儿童类型1个糖尿病（平均年龄134±30岁; 625％的男性）参加了MDI方案的儿童的阵营（连续皮下胰岛素输注和800％的日常注射MDI），719％被IDEG作为基础胰岛素治疗含有肺碱U100（Iglar）的281％（Iglar）所有患者均使用LISPRO或Aspart作为营地的缺点胰岛素日常计划包括教育课程，体育锻炼，3个主要餐点和2个零食，根据现有指导修订IGLAR和缺乏胰岛素剂量。 ，而IDEG剂量根据到达的经验个体化方法修订，但在22名参与者（194±105％）中减少了胰岛素剂量，而剂量增加17名儿童（+ 178± 127％）基于个体需求，在平均血糖和葡萄糖可变性中没有出现统计学上显着的差异，在IDEG组中发现了低血糖血症的风险过量患者该研究表明当与适当的糖尿病教育相关时不同胰岛素计划的类似效果和安全性管理，灵活的剂量调整尽管它越来越长，但缺乏验证的算法，IDEG与低血糖的风险过剩无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号